ACLY and atherosclerosis: lipids and beyond

EAS Office · November 1, 2022

A tailor-made programme, exclusively for invited members of Daiichi-Sankyo scientific and medical team

This training programme is exclusively for invited members members of the Daiichi-Sankyo scientific and medical team. Our goal with this exciting programme is to update you to the best possible level, to prepare for the presentation of the results of the CLEAR Outcomes trial in March 2023.

The Scientific Director of the programme is former President of the EAS, Prof Alberico L. Catapano, Milan, Italy. Here, in the video below, he describes what you will learn from it.

In our specially created programme, the faculty – selected experts from the EAS scientific community – take you through the development of new approaches to lipid lowering and cardiovascular risk, presenting the most recent data, and identifying emerging trends. We will discuss together what we can expect from the randomised clinical trial with cardiovascular outcomes that will be presented at the meeting of the American College of Cardiology 2023.

The programme is in two parts:

  • Part 1: Available now. A short online curriculum comprising five on-demand modules for invited participants to work through prior to…
  • Part 2: A meeting 13-14 February, 2023. Separate registration is required, invited participants only.

Sign in required.

At your own pace, work through these online modules to refresh your knowledge in the area in advance of the February meeting.

Separate registration required, invited participants only.

Frankfurt, 13-14 Feb 2023. A deep dive into the use of bempedoic acid in cardiovascular disease therapy, including sessions to challenge you about what you have learned and how you interpret all of the information that has been discussed.

The full programme is as follows:

13 Feb
14:00Welcome & Opening
Kausik Ray & Alberico L. Catapano
14:10Lipid lowering and diabetes
Lale Tokgozoglu
14:50Lipid Lowering and CRP: how important?
Maciej Banach
15:50Bempedoic Acid: mechanism of action
Stephen Pinkosky
16:30Genetic data
Alberico L Catapano
17:30Bempedoic Acid: a bird’s-eye view of clinical development
Bill Sasiela
18:10Interaction with statins
Alberico L. Catapano
18:50Summary & Wrap up
Kausik Ray & Alberico L. Catapano
14 Feb
08:00Welcome & Opening
Kausik Ray & Alberico Catapano
08:10CLEAR Outcomes – study design, its implications and
what are we expecting (CTT meta-analysis)
Kausik Ray
08:50Efficacy & safety
Ulrich Laufs
09:50Place in therapy: Round Table
All EAS Speakers
10:55Role play – FAQs – what to say when faced by a non-believer
Main topics:
• Anti-inflammatory effects
• Efficacy & safety 
• LDL reduction
• The Clear Outcome data: only for statin intolerant patients?
12:15Question time
All EAS Speakers
12:45Closing remarks
Kausik Ray & Alberico Catapano

About Instructor

EAS Office

9 Courses

Not Enrolled
This course is currently closed

Course Includes

  • 5 Modules
  • 10 Steps
  • 5 Tests